Mark Anderson is a Cardiology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
81 Highland Ave
Salem, MA 019702714
Telephone
978-744-5900Provider last certified this registry record 27 Apr 2022.
Clinical trials
- The Use of Impella RP Support System in Patients With Right Heart Failure
Sponsor: Abiomed Inc.
- RECOVER I Impella RECOVER LP/LD 5.0 Support System Safety and Feasibility Study
Sponsor: Abiomed Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AtriCure, Inc.Program year20251 payment
- ATRICURE, INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
75.8%Beta blocker19.6%Metoprolol Succinate80%Metoprolol Tartrate6%Carvedilol5%Sotalol4%Atenolol3%Nadolol2%Part D<11 patientsStatin13.8%Atorvastatin Calcium63%Rosuvastatin Calcium27%Pravastatin Sodium7%Simvastatin3%Part D<11 patients+ 15 more classes in this area
Blood & clotting
17.6%Factor Xa inhibitor12.9%Eliquis82%Xarelto18%Part D≥115 patientsP2Y12 inhibitor2.8%Clopidogrel75%Brilinta25%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
4.4%SGLT2 inhibitor2.2%Jardiance100%Part D≥21 patientsPotassium supplement2.2%Potassium Chloride64%Klor-Con M1020%Klor-Con M2016%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2002–2003 per NIH RePORTER. The latest:
- Role of the AIRE Gene in the Development of Autoimmunity
Joslin Diabetes Center
FY2003$123,290K08DK059958 - Role of the AIRE Gene in the Development of Autoimmunity
Joslin Diabetes Center
FY2002$120,776K08DK059958
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”